• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Bon Natural Life Limited

    6/3/25 9:00:02 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BON alert in real time by email
    6-K 1 form6-k.htm 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    For the month of June 2025

     

    Commission File Number 001-40517

     

    BON NATURAL LIFE LIMITED

    (Translation of registrant’s name into English)

     

    Room 601, Block C, Gazelle Valley, No.69, Jinye Road

    High-Tech Zone, Xi’an, Shaanxi, China

    People’s Republic of China

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒ Form 40-F ☐

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

     

    Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

     

    Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

     

     

     

     

     

     

    Share Repurchase Program

     

    On May 31, 2025, the Board of Directors of Bon Natural Life Limited (the “Company”) authorized a share repurchase program pursuant to a Purchase Plan Agreement (the “Agreement”) by and between the Company and TradeUp Securities (“TradeUp”) under which the Company may repurchase up to $1 million of its Class A ordinary shares (the “Share Repurchase Program”). The timing and actual number of shares repurchased will depend on a variety of factors including price, corporate and regulatory requirements, market conditions and other corporate liquidity requirements and priorities. Share repurchases may be executed through various means in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The Share Repurchase Program does not obligate the Company to purchase any particular number of shares and there is no guarantee as to the exact number of shares that will be repurchased by the Company.

     

    Pursuant to the Agreement, the Company appointed TradeUp as its exclusive agent to purchase securities.

     

    The Agreement and Share Repurchase Program will terminate on the earlier of (i) the one year anniversary of the execution date, (ii) the completion of all purchases contemplated by the Share Repurchase Program, (iii) termination by written notice of either party, (iv) any legal or regulatory restriction, (v) a merger, acquisition or similar transaction of the Company, (vi) a liquidation, bankruptcy or reorganization of the Company, or (vi) failure by the Company to perform its obligations under the Agreement.

     

    The Company will not purchase any shares outside of the Share Repurchase Program nor will it enter into any form of similar plan. The Company also agreed to customary indemnification provisions for the benefit of TradeUp.

     

    The Company will pay TradeUp a fee of US$0.015 per share for any securities purchased.

     

    Item 9.01. Financial Statements and Exhibits.

     

    Exhibits

     

    The following exhibits are included in this Form 6-K:

     

    Exhibit No.   Description of Exhibit

    99.1

     

    Press Release dated June 3, 2025

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Date: June 3, 2025 Bon Natural Life Limited
         
      By: /s/ Yongwei Hu
        Yongwei Hu
        Chairman and Chief Executive Officer

     

     

    Get the next $BON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BON

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BON
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BON Announces Share Repurchase Program for up to US$1.0 Million

      XI'AN, China, June 03, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced its board of directors approved a share repurchase program pursuant to which the Company may purchase up to $1.0 million of its Class A ordinary shares. Under the share repurchase program, the Company is authorized to repurchase its shares from time to time in the open market. The timing and actual number of shares repurchased will depend on a variety of factors including price, corporate and regulatory requirements, market conditions and other corporate liquidity requir

      6/3/25 9:00:00 AM ET
      $BON
      Medicinal Chemicals and Botanical Products
      Health Care
    • BON Announces Launch of Tea Pigment Digestive Health Products and Cooperation Agreement Signed with Shanghai Risesun International Trade

      XI'AN, China, May 22, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced a non-exclusive sales cooperation agreement with Shanghai Risesun International Trade Co., Ltd., a leading functional ingredient distributor in China. The term of the Agreement is 24 months with a total contract value of US$ 24 million. Pursuant to the agreement, Shanghai Risesun will market, distribute and sell BON's tea pigment series health products in China. Leveraging a robust biological profile that includes lipid modulation, glycemic control, antioxidant activity,

      5/22/25 9:00:00 AM ET
      $BON
      Medicinal Chemicals and Botanical Products
      Health Care
    • BON Announces The Launch Of Its Postbiotic Hypoglycemic Patented Ingredient Product Series And Its Cooperation Agreement

      XI'AN, China, May 16, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, announced an exclusive cooperation agreement with Beijing Huahai Keyuan (Tech) Co., Ltd., a leading functional ingredient distributor in China. The term of the agreement is 36 months with a total contract value of 32 million US dollars. Pursuant to the agreement, Beijing Huahai Keyuan will serve as the exclusive sales partner of BON's postbiotic hypoglycemic ingredients. BON aims to expand into the global blood sugar health market through the development of a series of innovative hypoglyc

      5/16/25 9:00:00 AM ET
      $BON
      Medicinal Chemicals and Botanical Products
      Health Care

    $BON
    SEC Filings

    See more
    • SEC Form 6-K filed by Bon Natural Life Limited

      6-K - Bon Natural Life Ltd (0001816815) (Filer)

      6/3/25 9:00:02 AM ET
      $BON
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by Bon Natural Life Limited

      6-K - Bon Natural Life Ltd (0001816815) (Filer)

      5/22/25 3:16:58 PM ET
      $BON
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by Bon Natural Life Limited

      6-K - Bon Natural Life Ltd (0001816815) (Filer)

      5/16/25 9:05:19 AM ET
      $BON
      Medicinal Chemicals and Botanical Products
      Health Care

    $BON
    Financials

    Live finance-specific insights

    See more
    • Bon Natural Life Limited Announces FY2022 Earnings Release Date and Webcast

      Earnings to be released before market opens on Friday, February 10, 2023 XIAN, China, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, will issue its FY2022 earnings release for the fiscal year ended September 30, 2021 before the market open on Friday, February 10, 2023. BON will also host an investor conference call and webcast on the same date, beginning at 9:00 a.m. EST. Management on the call will include CEO Mr. Richard (Yongwei) Hu, CFO Mr. Zhenchao Li, COO Ms. Yingchun Xue and CMO Wenjuan Chen. A replay of the call will also be

      2/7/23 8:30:00 AM ET
      $BON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bon Natural Life Limited Announces 2022 Half-Year Earnings Release Date and Webcast

      Earnings to be released before market opens on Monday, August 1, 2022XIAN, China, July 28, 2022 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, will issue its half-year earnings release for the reporting period ended March 31, 2022 before the market open on Monday, August 1, 2022. BON will also host an investor conference call and webcast on the same date, beginning at 9:00 a.m. EST. Management on the call will include CEO Mr. Richard (Yongwei) Hu, CFO Mr. Zhenchao Li, COO Ms. Yingchun Xue and CMO Wenjuan Chen. A replay of the call will also be archived o

      7/28/22 4:30:00 PM ET
      $BON
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bon Natural Life Limited Announces FY2021 Earnings Release Date and Webcast

      Earnings to be released before market opens on Monday, January 31, 2022 XI'AN, China, Jan. 28, 2022 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, will issue its FY2021 earnings release for the fiscal year ended September 30, 2021 before the market open on Monday, January 31, 2022. In observation of Chinese New Year, BON will host an investor conference call and webcast on February 3 beginning at 9:00 a.m. EST. Management on the call will include CEO Mr. Richard (Yongwei) Hu, CFO Mr. Zhenchao Li, CMO Ms. Wenjuan Chen and COO Ms. Yingchun Xue. A replay

      1/28/22 9:00:00 AM ET
      $BON
      Medicinal Chemicals and Botanical Products
      Health Care

    $BON
    Leadership Updates

    Live Leadership Updates

    See more
    • Bon Natural Life Limited Appoints Wallace Lee as New Chief Financial Officer

      XIAN, China, April 25, 2023 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, is pleased to announce the appointment of Mr. Wallace Lee as Chief Financial Officer (CFO), effective April 17, 2023. Mr. Lee succeeds Zhenchao Li, who stepped down from the role of CFO after a 4-year career with the Company, effective April 17, 2023. "We welcome Wallace Lee into BON's executive leadership team." Commented Richard Hu, "Wallace brings exceptional financial, strategic, and operational experience both from multiple industry sectors and experience as a public c

      4/25/23 8:30:00 AM ET
      $BON
      $SXTC
      $WSG
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Services-Misc. Amusement & Recreation
    • Bon Natural Life Limited Announces Change to Board Composition

      XIAN, China, June 30, 2022 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced the appointment of Jeffrey Guzy, as a new independent Director to its Board of Directors and as Chair of the Audit Committee, both effective June 28, 2022. Effective June 27, 2022, Mr. Christopher Constable resigned as a director of the Company for personal reasons and stepped down as a member and chairman of the audit committee of the Board. The resignation of Mr. Constable did not result from any dispute or disagreement with the Company or the Board on any matter

      6/30/22 4:30:00 PM ET
      $BON
      Medicinal Chemicals and Botanical Products
      Health Care